10-Year ASCVD Risk Stratification Matrix v2.0
ACC/AHA Cardiovascular Risk & Guideline-Directed Statin Initiation
📈 Primary Prevention Engine: Evaluates the 10-year risk of primary atherosclerotic cardiovascular disease (myocardial infarction or stroke) in patients aged 40–79 without established ASCVD.
1 Patient Demographics
2 Biomarkers & History
📚 Pathway Architecture & Clinical Pearls
1. The Pooled Cohort Equations (PCE)
ASCVD Risk-Enhancing Factors
This engine utilises the 2013 ACC/AHA Pooled Cohort Equations to predict the absolute 10-year risk of a first hard ASCVD event (nonfatal myocardial infarction, CHD death, or fatal/nonfatal stroke). It is the foundational step for primary prevention lipid management.
⚠ The LDL-C ≥ 190 Trap
Do not use this algorithm if the patient has a baseline LDL-C ≥ 190 mg/dL. These patients have presumed familial hypercholesterolaemia and mandate immediate high-intensity statin therapy regardless of their calculated 10-year risk.
Do not use this algorithm if the patient has a baseline LDL-C ≥ 190 mg/dL. These patients have presumed familial hypercholesterolaemia and mandate immediate high-intensity statin therapy regardless of their calculated 10-year risk.
💡 The Diabetic Mandate
For patients aged 40-75 with Diabetes Mellitus, the decision to start a statin is already made by the guidelines (moderate-intensity minimum). The PCE score is strictly used to determine if they need escalation to a high-intensity statin (if 10-year risk is ≥20%).
ACC/AHA Primary Prevention ThresholdsFor patients aged 40-75 with Diabetes Mellitus, the decision to start a statin is already made by the guidelines (moderate-intensity minimum). The PCE score is strictly used to determine if they need escalation to a high-intensity statin (if 10-year risk is ≥20%).
| Risk Category | 10-Year Risk | Clinical Recommendation |
|---|---|---|
| Low Risk | < 5% | Emphasise healthy lifestyle. Statin not typically recommended. |
| Borderline Risk | 5% to <7.5% | If risk enhancers are present, consider moderate-intensity statin. |
| Intermediate Risk | 7.5% to <20% | Initiate moderate-intensity statin (reduce LDL-C by ≥30%). |
| High Risk | ≥ 20% | Initiate high-intensity statin (reduce LDL-C by ≥50%). |
The presence of these factors strongly favours statin initiation in patients at Borderline or Intermediate risk:
- Patient History: Family history of premature ASCVD (males <55, females <65); High-risk ethnicities (e.g., South Asian ancestry).
- Clinical Conditions: Metabolic syndrome; Chronic Kidney Disease (eGFR 15-59); Chronic inflammatory conditions (Rheumatoid arthritis, psoriasis, HIV); History of premature menopause or pre-eclampsia.
- Biomarkers & Lipids: Persistent hypertriglyceridaemia (≥175 mg/dL); hs-CRP ≥2.0 mg/L; elevated Lp(a) ≥50 mg/dL; elevated ApoB ≥130 mg/dL; ABI <0.9.
| Intensity | LDL-C Target | Common Daily Dosing |
|---|---|---|
| High | ≥ 50% reduction | Atorvastatin 40–80 mg Rosuvastatin 20–40 mg |
| Moderate | 30% – 49% reduction | Atorvastatin 10–20 mg Rosuvastatin 5–10 mg |
Abbreviations: ASCVD (Atherosclerotic Cardiovascular Disease) · TC (Total Cholesterol) · HDL (High-Density Lipoprotein) · SBP (Systolic Blood Pressure) · CHD (Coronary Heart Disease)
⚠ Clinical Disclaimer: Validated strictly for primary prevention in patients aged 40-79. Not applicable for secondary prevention (patients with established ASCVD). The PCE historically underestimates risk in South Asian populations. Always employ shared decision-making.
© 2026 Dr Shashikiran Umakanth · MEDiscuss.org · All rights reserved.
10-Year ASCVD Risk Stratification Matrix — Clinical decision support for educational purposes. Unauthorised reproduction, redistribution, or modification of this tool is prohibited. For permissions, contact mediscuss.org/contact.
Algorithm References & Evidence Base
- Goff DC Jr, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk. Circulation. 2014;129(25 Suppl 2):S49-73.
- Grundy SM, et al. 2018 AHA/ACC/… Guideline on the Management of Blood Cholesterol. J Am Coll Cardiol. 2019;73(24):e285-e350.
- Arnett DK, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. Circulation. 2019;140(11):e596-e646.
MEDiscuss Clinical Decision Support Suite
Access all evidence-based algorithms, prognostic matrices, and pharmacotherapeutic pathways.
← View All Clinical Modules
